Research progress on radiotherapy and chemotherapy combined with immunotherapy for locally advanced esophageal squamous cell carcinoma.
- Author:
Fanwei MENG
1
Author Information
1. Department of Radiation Oncology, Suzhou First People's Hospital, Suzhou 234000, China. *Corresponding author, E-mail: 270832850@qq.com.
- Publication Type:English Abstract
- MeSH:
Humans;
Esophageal Squamous Cell Carcinoma/therapy*;
Esophageal Neoplasms/radiotherapy*;
Immunotherapy/methods*;
Chemoradiotherapy/methods*;
Combined Modality Therapy
- From:
Chinese Journal of Cellular and Molecular Immunology
2025;41(11):1047-1054
- CountryChina
- Language:Chinese
-
Abstract:
The standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) is neoadjuvant chemoradiotherapy, followed by surgery or definitive radiotherapy, but clinical results are unsatisfactory. In recent years, relevant studies have shown that immunotherapy combined with chemoradiotherapy has become a new treatment option for locally advanced ESCC. This article summarizes the current progress of chemoradiotherapy combined with immunotherapy in the treatment of locally advanced ESCC, and provides necessary theoretical basis for the comprehensive understanding and optimization of chemoradiotherapy combined with immunotherapy regimens for ESCC.
